Adverse event reporting patterns associated with Degarelix and Relugolix: a pharmacovigilance study based on the FAERS database

Background：Degarelix and Relugolix are two GnRH antagonists approved by the FDA for androgen deprivation therapy (ADT) in the treatment of prostate cancer. However, differences in their safety profiles and the characteristics of specific adverse events (AEs) remain insufficiently characterized. Methods：This study analyzes adverse events (AEs) associated with Degarelix and Relugolix reported in the FAERS from Q1 2009 through Q2 2024. Multiple signal detection methods, including reporting odds...